Ironwood Pharma (IRWD) Tops Q3 EPS by 6c; Trims Cash Burn Outlook

November 3, 2016 8:41 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $66.1 million versus the consensus estimate of $60.01 million.

Ironwood now expects to use less than $50 million in cash for operations in 2016, down from previous guidance of less than $70 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment